ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Best practice in precision medicine for prostate cancer

ESMO 2025: Latest in EGFR mutant NSCLC

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival